Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) - Zacks Research raised their Q2 2025 earnings per share estimates for Pediatrix Medical Group in a report issued on Monday, March 10th. Zacks Research analyst Z. Masood now anticipates that the company will earn $0.39 per share for the quarter, up from their previous forecast of $0.38. The consensus estimate for Pediatrix Medical Group's current full-year earnings is $1.38 per share. Zacks Research also issued estimates for Pediatrix Medical Group's FY2025 earnings at $1.41 EPS, Q3 2026 earnings at $0.37 EPS and FY2027 earnings at $1.26 EPS.
Pediatrix Medical Group (NYSE:MD - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The company reported $0.49 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.37 by $0.12. Pediatrix Medical Group had a positive return on equity of 15.47% and a negative net margin of 4.92%. The firm had revenue of $502.36 million for the quarter, compared to analysts' expectations of $486.22 million.
Other analysts have also issued reports about the stock. Macquarie started coverage on shares of Pediatrix Medical Group in a report on Monday, December 16th. They issued an "outperform" rating and a $18.00 price objective for the company. UBS Group upped their price objective on Pediatrix Medical Group from $16.50 to $18.50 and gave the company a "neutral" rating in a research report on Friday, February 21st. StockNews.com raised Pediatrix Medical Group from a "hold" rating to a "buy" rating in a research report on Wednesday, January 22nd. Mizuho upped their price objective on Pediatrix Medical Group from $13.00 to $15.00 and gave the company a "neutral" rating in a research report on Tuesday, November 19th. Finally, Truist Financial upped their price objective on Pediatrix Medical Group from $15.00 to $18.00 and gave the company a "hold" rating in a research report on Friday, February 21st. Four analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, Pediatrix Medical Group currently has a consensus rating of "Hold" and an average price target of $17.08.
View Our Latest Research Report on MD
Pediatrix Medical Group Stock Down 2.4 %
NYSE MD opened at $14.01 on Wednesday. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.60 and a quick ratio of 1.42. The stock has a market capitalization of $1.20 billion, a PE ratio of -11.67, a PEG ratio of 1.74 and a beta of 1.48. Pediatrix Medical Group has a 1 year low of $6.62 and a 1 year high of $17.67. The business's 50-day moving average is $14.12 and its 200 day moving average is $13.37.
Institutional Investors Weigh In On Pediatrix Medical Group
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Pacer Advisors Inc. bought a new position in Pediatrix Medical Group in the 4th quarter worth $35,492,000. American Century Companies Inc. lifted its holdings in shares of Pediatrix Medical Group by 628.2% in the 4th quarter. American Century Companies Inc. now owns 1,739,323 shares of the company's stock valued at $22,820,000 after acquiring an additional 1,500,485 shares during the last quarter. Oberweis Asset Management Inc. bought a new position in shares of Pediatrix Medical Group in the 4th quarter valued at about $6,122,000. Renaissance Technologies LLC lifted its holdings in shares of Pediatrix Medical Group by 117.4% in the 4th quarter. Renaissance Technologies LLC now owns 838,800 shares of the company's stock valued at $11,005,000 after acquiring an additional 453,000 shares during the last quarter. Finally, Boston Partners lifted its holdings in shares of Pediatrix Medical Group by 25.2% in the 4th quarter. Boston Partners now owns 1,956,353 shares of the company's stock valued at $25,922,000 after acquiring an additional 393,600 shares during the last quarter. 97.71% of the stock is currently owned by hedge funds and other institutional investors.
About Pediatrix Medical Group
(
Get Free Report)
Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pediatrix Medical Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pediatrix Medical Group wasn't on the list.
While Pediatrix Medical Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
